Farxiga Cuts A1c in Pediatric Diabetes; Late-Stage CAH Win; At-Home Menopause Test

Derick Alison
Derick Alison
3 Min Read

Dapagliflozin (Farxiga) lowered HbA1c by 1.03 percentage points more than placebo in children and adolescents with type 2 diabetes, while saxagliptin (Onglyza) showed no significant reduction versus placebo, the phase III T2NOW trial showed. (NEJM Evidence)

Those findings were also presented at the European Association for the Study of Diabetes annual meeting — catch up on coverage from the meeting here.

Drugmakers warned European regulators that a proposed ban on PFAS — also known as “forever chemicals” — would halt the pharmaceutical industry in the region. (Reuters)

A phase III study showed that the oral selective corticotropin-releasing factor type 1 receptor antagonist crinecerfont significantly decreased serum androstenedione after a glucocorticoid-stable period in kids with congenital adrenal hyperplasia (CAH), Neurocrine Biosciences announced.

The FDA cleared Biomea Fusion to study an investigational covalent menin inhibitor as a type 1 diabetes treatment, according to the company.

But the agency declined to approve a biosimilar insulin aspart product, said India-based Biocon Biologics.

Patients who took GLP-1 receptor agonists for weight loss had a nine times higher risk of pancreatitis compared with those who took the older combination drug bupropion-naltrexone (Contrave), as well as greater risks of bowel obstruction and gastroparesis. (JAMA)

The Osteoporosis Canada 2023 Guideline Update Group released its latest clinical practice guideline for the management of osteoporosis and fracture prevention. (CMAJ)

Does the at-home menopause test really work? (New York Times)

A Florida judge dismissed Novo Nordisk’s lawsuit over compounded versions of semaglutide (Ozempic, Wegovy). (Seeking Alpha)

After years of hearing doctors blame her lupus symptoms on her weight, a Florida woman underwent bariatric surgery and lost half of her body weight — only to find her symptoms were worse than ever. (People)

The number of U.S. employers covering obesity drugs may double next year. (Reuters)

During the first 7 months of the year, drugmakers spent nearly $500 million on ads for obesity and diabetes drugs. (CNBC)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.

Source link

Share this Article
Leave a comment
adbanner